Recent study has identified a predictive gene signature, which determines sensitivity to MDM2 inhibition by DS-3032b, and validated it in patient-derived tumor xenograft (PDX) models and ex vivo in human AML cells. This evidence concerns the gene MDM2 and neoplasm.